A Multicenter Study Based on Multi-omics Analysis to Predict the Early Prognosis and Recurrence Risk of Acute Ischemic Stroke

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

400 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-01-30

Study Completion Date

2028-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Through a multicenter prospective AIS cohort study, we analyze the potential association of human proteome, microbiome and metabolome alterations with AIS prognosis, searching for key proteins, differential organisms and metabolites, combining experimental data at multiple molecular levels with computational models, and establishing early prediction models through machine learning-based prediction algorithms. While closely tracking the recurrence of stroke in AIS patients, we evaluate the predictive value of human proteome, microbiome and metabolites for stroke recurrence through a nested case-control study, which provides key reference information for exploring the unknown residual risk of AIS recurrence.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Dynamic Changes of the Human Microbiome Predict the Risk of Poor Prognosis in Patients With Acute Ischemic Stroke: a Multi-center Study

NCT04978701

Acute Ischemic Stroke

UNKNOWN

Predictive Value of Human Microbiome and Serological Markers for Clinical Outcome of AIS With Active Cancer

NCT05553990

Ischemic Stroke, Acute Tumor Progression

UNKNOWN

The Screening of Neuroprotective Biomarkers After Acute Ischemic Stroke

NCT05689528

Acute Ischemic Stroke

COMPLETED

Prospective Cohort Control Study on Changes in Gut Microbiota in Ischemic Stroke

NCT07247838

Ischemic Stroke

RECRUITING

Gut Microbiota and Serum Markers for Cognitive Impairment and Poor Prognosis After Ischemic Stroke

NCT04688138

Ischemic Stroke

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Currently, the burden of brain vascular disease in China is the highest in the world, and among them, the incidence rate of acute ischemic stroke (AIS) is high, the recurrence rate is high, the disability rate is high, the mortality rate is high, and the social burden is heavy. With the increasing number of AIS patients, how to effectively prevent and treat them is a huge challenge facing us. The occurrence and development of AIS are caused by the joint action of multiple risk factors and mutual influence, and single technical means are difficult to deeply explore its complex mechanism. Therefore, building a risk prediction model for poor prognosis and recurrence based on multi-omics technology and layering risk factors for patients are the important research directions for the future. This study aims to establish a multi-center cohort by collecting fecal and blood samples from AIS patients and conducting proteomic, microbial and metabolomic detection. It records the prognosis and recurrence events and uses cross-omics analysis technology to explore the multi-omics network molecular mechanism and screen for new intervention targets. It establishes an early prediction model and explores the stroke secondary prevention strategy based on multi-omics data.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Ischemic Stroke, Acute

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

modeling queue

The modeling queue is used to manage and prioritize tasks related to the development and training of models.

microbiome; metabolomics; proteomics

Intervention Type OTHER

post-stroke change of microbiome; metabolomics; proteomics

validation queue

The validation queue is designed to handle tasks related to the evaluation and validation of models.

microbiome; metabolomics; proteomics

Intervention Type OTHER

post-stroke change of microbiome; metabolomics; proteomics

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

microbiome; metabolomics; proteomics

post-stroke change of microbiome; metabolomics; proteomics

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Meet the diagnostic criteria of AIS according to the Chinese Guidelines for the Diagnosis and Treatment of Acute Ischemic Stroke 2018
2. Aged 18 to 75 years old
3. Stroke within 7 days of onset
4. Sign informed consent, provide relevant medical history information and provide biological specimens

Exclusion Criteria

1. Severe impairment of consciousness (awareness score of NIHSS\>1)
2. History of stroke within 12 months
3. Severe systemic disease including malignancy
4. ALT or AST\> 2 times the upper limit of normal or severe liver disease
5. creatinine \> 1.5 times the upper limit of normal or severe kidney disease
6. History of long-term drinking, drug use, and chemical poisoning (e.g., pesticide poisoning); Note: Long-term alcohol consumption, usually more than 5 years, over 40 g/day of alcohol for men and 20 g/day for women, or a history of heavy alcohol consumption within 2 weeks, over 80 g/day of alcohol
7. History of intestinal tumors, irritable bowel syndrome or inflammatory bowel disease or confirmed in the hospital
8. Unable to collect a stool specimen within 4 days of admission
9. Assessed to be unsuitable for participation in this study by the investigator

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No